Abstract |
Mitoxantrone ( mitox) has been shown to be effective for secondary progressive (SP) and relapsing-remitting multiple sclerosis (MS). The aim of this open trial was to evaluate the effects of combined mitox and methylprednisolone (MP) therapy on patients with primary progressive (PP)-MS or with SP-MS. We present here the results of an interim analysis done after the study had lasted 5 years. Sixty-five patients (20 with PP-MS and 45 with SP-MS) have been included so far. The treatment involved ten cycles of combined mitox and MP. The intervals between the individual cycles were systematically prolonged from 3 months initially to 12 months, so the complete treatment took a total of 57 months. Conclusion This interim analysis indicates that mitox combined with MP beneficially reduces the progression of disability in patients with PP-MS and SP-MS. Therefore, this therapy regimen can also be considered a feasible option for PP-MS.
|
Authors | V C Zingler, M Strupp, K Jahn, A Gross, R Hohlfeld, T Brandt |
Journal | Der Nervenarzt
(Nervenarzt)
Vol. 76
Issue 6
Pg. 740-7
(Jun 2005)
ISSN: 0028-2804 [Print] Germany |
Vernacular Title | Kombinierte Mitoxantron-/Methylprednisolon-Behandlung bei primär und sekundär chronisch progredienter Multipler Sklerose. Eine Anwendungsbeobachtung bei 65 Patienten. |
PMID | 15803287
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Analgesics
- Drug Combinations
- Mitoxantrone
- Methylprednisolone
|
Topics |
- Adult
- Aged
- Analgesics
(administration & dosage)
- Disease Progression
- Drug Combinations
- Female
- Humans
- Male
- Methylprednisolone
(administration & dosage)
- Middle Aged
- Mitoxantrone
(administration & dosage)
- Multiple Sclerosis, Chronic Progressive
(drug therapy, prevention & control)
- Prognosis
- Recovery of Function
(drug effects)
- Secondary Prevention
- Treatment Outcome
|